Clinical Trial

S0820, Adenoma and Second Primary Prevention Trial

Study acronym: PACES
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Protocol Amendment History 40 amendments
This ClinicalTrials.gov record has been amended 40 times since 2011-05-06; most recent amendment 2026-04-01.
Status change: Recruiting → Active, Not Recruiting 2023-10-04
Status change: Active, Not Recruiting → Recruiting 2013-04-09
Status change: Not Yet Recruiting → Active, Not Recruiting 2013-04-08
Trial Details
NCT Number NCT01349881
Lead Sponsor SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI), Cancer Prevention Pharmaceuticals, Inc.
Conditions Colorectal Neoplasms
Enrollment 354 participants
Start Date 2013-08-23
Primary Completion 2027-09-15 (estimated)
Study Completion 2032-02-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-02